Oxford, UK - British techbio innovator Etcembly has launched a groundbreaking new research study aiming to uncover new targets for cancer immunotherapies by analysing the immune cells of cancer survivors.
The ETCh study is recruiting people aged 18-65 who are living with or have survived cancer to join the study, as well as healthy volunteers. Participants will be asked to donate a small amount of blood up to five times over the course of one year, and provide information about their health.
The ETCh study is rooted in the well-established concept that long-term survivors have beaten cancer due to their immune system’s ability to recognise and eliminate cancerous cells. However, a systematic search for the specific targets recognised within tumours has yet to be undertaken.
In this study, blood samples will be collected from people who are living with or have survived cancer as well as healthy individuals. The research team will conduct...